Trial Profile

A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 28 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Retifanlimab (Primary) ; Tuparstobart (Primary) ; Verzistobart (Primary)
Indications Malignant melanoma; Solid tumours
Focus Adverse reactions; Proof of concept; Therapeutic Use
Sponsors Incyte Corporation

Most Recent Events

21 Nov 2023 Status changed from recruiting to active, no longer recruiting.
06 Sep 2023 Planned primary completion date changed from 21 Jul 2023 to 4 Aug 2025.
01 Aug 2023 According to an Incyte Corporation media release, discovery of INCAGN2385 is in collaboration with Agenus

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com